The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 24 cents per share. The clinical-stage biotech company that develops stem cell treatments posted revenue of $1 million in the period, meeting Street…
News
- Fate Therapeutics reports 4Q loss
- Can the Bernie Sanders 'Our Revolution' Put Progressive Populism Back Into the Texas ...
... Rick Trevino for the 23rd Congressional District that stretches from San Antonio west to El Paso; Derrick Crowe in the crowded field for the 21st Congressional District that goes from San Antonio to Austin; and Northern style kung fu practitioner and biomedical PhD…
- Local LGBT Candidates Look Toward Primary Election
He received a Masters of Science from the University of Texas at San Antonio and was an adjunct faculty member at San Antonio College for seven years. His career includes stints at Southwest Analytical Concepts, Southwest Foundation for Biomedical Research, and the Texas Commission on Alcohol…
- An experimental acne drug just failed two key clinical trials — and the stock's getting obliterated ...
Dermatology biotech Dermira said on Monday that its experimental drug to treat acne failed two key clinical trials. Dermira was studying the drug in kids over 9 ... San Antonio Express-News; Arrest made on mysterious death of Trinity University cheerleader's... San Antonio Express-News; Lines…
- City Council needs independent research agency
San Antonio is a city in transition. After years of being summed up simply as a sleepy, blue-collar town, the Alamo City has come into its own as a leader in several key industries — from manufacturing, to bioscience, to cybersecurity and information technology. We are a city on the rise, and a…